BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Saturday, January 31, 2026
Breaking News: BioWorld Science 2025 Year in Review
See today's BioWorld Science
Home
» Rayzebio nominates first-in-class peptide drug candidate against GPC3 for hepatocellular carcinoma
To read the full story,
subscribe
or
sign in
.
Cancer
Rayzebio nominates first-in-class peptide drug candidate against GPC3 for hepatocellular carcinoma
March 22, 2023
Rayzebio Inc. has nominated a first-in-class novel peptide drug candidate against glypican-3...
BioWorld Science
Cancer
Peptide